Egypt is accelerating its drive to become a regional pharmaceutical powerhouse, with the government stepping up collaboration with the Arab Company for Drug Industries and Medical Appliances (ACDIMA) to boost production, secure self-sufficiency in essential medicines, and expand exports to new international markets.
The announcement came during a high-level meeting in New Alamein City, where Health Minister Khaled Abdel Ghaffar met with fellow ministers and ACDIMA executives to discuss the company’s performance and expansion strategy.
Minister Abdel Ghaffar underscored that greater investment in domestic drug production is central to Egypt’s long-term healthcare and economic strategies. “By reinforcing cooperation with ACDIMA, we are not only ensuring access to essential medicines but also laying the foundation for Egypt to serve as a regional hub for pharmaceutical manufacturing,” he said.
According to government sources, the plan includes expanding the scope of biological medicines, one of the fastest-growing areas of global drug demand, alongside securing new contracts with multinational pharmaceutical firms to produce medicines locally under technology-transfer agreements.
Egypt’s pharmaceutical exports, currently estimated at over $400 million annually (according to the Egyptian Drug Authority), remain modest compared to regional peers like Turkey. However, officials argue that scaling up partnerships with ACDIMA—whose portfolio spans over 200 products—could propel Egypt into larger markets across Africa, the Middle East, and potentially Europe.
Industry analysts view this as a strategic pivot, not only to reduce dependency on imported drugs but also to capitalize on Egypt’s geographic position and relatively low production costs.
“Egypt is uniquely positioned to become a bridge between African demand and global suppliers,” said Dr. Hossam Badrawi, a healthcare economist. “If the country manages to leverage ACDIMA’s scale and attract sustained foreign partnerships, pharmaceutical exports could easily double within the next five years.”
ACDIMA, established in 1976, has increasingly become central to Egypt’s industrial policy. Recent years have seen the company diversify into oncology and biologics, areas where Egypt previously relied heavily on imports.
At the New Alamein meeting, executives presented financial results showing stable growth and confirmed ongoing negotiations with international firms for joint manufacturing projects. Exclusive sources told Media that ACDIMA is also eyeing an expansion of its research and development footprint, with plans to open a new biologics research center by 2026—a move that could strengthen its competitiveness regionally.
The government’s push into pharmaceuticals aligns with Egypt’s broader Vision 2030 strategy, which prioritizes healthcare and industrial localization as pillars of economic resilience. By investing in medicine self-sufficiency, Cairo hopes to shield its health system from supply shocks like those experienced during the COVID-19 pandemic while boosting foreign currency earnings through exports.
“Egypt has a chance to become a serious player if it continues to align industrial investment with healthcare needs,” said Professor Amr Adly, a political economist at the American University in Cairo. “The real challenge will be maintaining quality standards that allow local products to meet European and Gulf regulatory benchmarks.”
With ACDIMA at the forefront, Egypt’s pharmaceutical ambitions appear to be shifting from vision to execution. If successful, the initiative could not only meet domestic health needs but also position Egypt as a regional leader in medicine production and innovation, opening doors to lucrative export markets and enhancing the country’s global standing in healthcare manufacturing.
